Targeted therapies of HER2-positive gastric adenocarcinoma

被引：1
|
作者：
Schulze, Arik Bernard [1 ]
Kerkhoff, Andrea [1 ]
Lenz, Georg [1 ]
Kessler, Torsten [1 ]
机构：
[1] Univ Hosp Muenster, Dept Med A Hematol Oncol & Pneumol, Munster, Germany
来源：
TRANSLATIONAL CANCER RESEARCH | 2017年 / 6卷
关键词：
TRASTUZUMAB EMTANSINE; 2ND-LINE TREATMENT; OPEN-LABEL; PHASE-III; CANCER; LAPATINIB; TRIAL; CAPECITABINE;
D O I：
10.21037/tcr.2017.09.03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S177 / S180
页数：4
相关论文
共 50 条
  • [41] Dual HER2-targeted approaches in HER2-positive breast cancer
    Eugene R. Ahn
    Charles L. Vogel
    Breast Cancer Research and Treatment, 2012, 131 : 371 - 383
  • [42] Targeted therapy in HER2-positive breast cancer (Review)
    Li, Shu Guang
    Li, Li
    BIOMEDICAL REPORTS, 2013, 1 (04) : 499 - 505
  • [43] Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
    Palle, Juliette
    Tougeron, David
    Pozet, Astrid
    Soularue, Emilie
    Artru, Pascal
    Leroy, Florence
    Dubreuil, Olivier
    Sarabi, Matthieu
    Williet, Nicolas
    Manfredi, Sylvain
    Martin-Babau, Jerome
    Rebischung, Christine
    Ben Abdelghani, Meher
    Evesque, Ludovic
    Dreanic, Johann
    Hautefeuille, Vincent
    Louafi, Samy
    Sefrioui, David
    Savinelli, Francesco
    Mabro, May
    Rousseau, Benoit
    Lecaille, Cedric
    Bouche, Olivier
    Louvet, Christophe
    Lecomte, Thierry
    Bonnetain, Franck
    Taieb, Julien
    Zaanan, Aziz
    ONCOTARGET, 2017, 8 (60) : 101383 - 101393
  • [44] HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy
    Shao, Qiangzu
    Deng, Junge
    Wu, Haoran
    Huang, Zeping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [45] HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
    Kaito, Akio
    Kuwata, Takeshi
    Tokunaga, Masanori
    Shitara, Kohei
    Sato, Reo
    Akimoto, Tetsuo
    Kinoshita, Takahiro
    WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (15) : 1964 - 1977
  • [46] HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
    Akio Kaito
    Takeshi Kuwata
    Masanori Tokunaga
    Kohei Shitara
    Reo Sato
    Tetsuo Akimoto
    Takahiro Kinoshita
    World Journal of Clinical Cases, 2019, (15) : 1964 - 1977
  • [47] Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies
    Mounsey, Louisa A.
    Deal, Allison M.
    Keith, Kevin C.
    Benbow, Julia M.
    Shachar, Shlomit S.
    Zagar, Timothy
    Dees, E. Claire
    Carey, Lisa A.
    Ewend, Matthew G.
    Anders, Carey K.
    CLINICAL BREAST CANCER, 2018, 18 (01) : 29 - 37
  • [48] Trastuzumab, pyrotinib and paclitaxel for HER2-positive breast cancer after multi-line targeted therapies
    Xu, Yan
    Ding, Li
    Li, Chao
    Zhang, Yongqiang
    MINERVA MEDICA, 2023, 114 (04) : 532 - 533
  • [49] Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
    Montagna, Emilia
    Colleoni, Marco
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [50] Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
    Zhifei Li
    Huan Zhao
    Huihui Hu
    Haili Shang
    Yongjing Ren
    Wenhui Qiu
    Hao Su
    Huifang Lyu
    Xiaobing Chen
    Chinese Journal of Cancer Research, 2024, 36 (03) : 306 - 321
12345